EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Richard R Watkins, Robert A Bonomo

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Richard R Watkins und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Northeast Ohio Medical University, Rootstown, OH, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Entasis Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of SUL-DUR, discussing its unique features and role in treating infections caused by CRAB pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAcinetobacter InfectionsHumansAnti-Bacterial AgentsSulbactamCarbapenemsMicrobial Sensitivity TestsDrug CombinationsAzabicyclo Compounds

Stichwörter der Autor:innen

antimicrobial resistancecarbapenem-resistant Acinetobacter baumanniisulbactam-durlobactam

Substanzen

Anti-Bacterial AgentsSulbactamCarbapenemssulbactam-durlobactamDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Northeast Ohio Medical University, Rootstown, OH, USA.
  • Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.
  • Case Western Reserve University-Cleveland VA Medical Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, OH, USA.

Förderung

  • Entasis Therapeutics

Zitieren

APA

Watkins, R. R., & Bonomo, R. A. (2023). Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad093

Vancouver

Watkins RR, Bonomo RA. Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad093

BibTeX
@article{Watkins2023,
  author = {Watkins, Richard R and Bonomo, Robert A},
  title = {Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad093}
}
Kostenlos starten →